Canada’s Neo Performance Materials is set to conduct a strategic review led by a special committee of independent directors.
The review will assess the company's strategy, assets, operations and capital structure, exploring various strategic alternatives that could include sales, divestitures, mergers or other business combinations.
Additionally, it will consider potential strategic investments, partnerships, JVs, changes in capital structure, capital allocation and other possible transactions.
The review will also evaluate the company's compensation plans to ensure they align with shareholder interests.
Neo produces the fundamental components of numerous contemporary technologies that improve sustainability.
Metals, alloys, speciality chemicals, magnetic powders and magnets are some of its industrial offerings.
Neo board chair Claire Kennedy said: “The board and management team of Neo are committed to investigating opportunities to maximise value for all shareholders.
“Neo’s business continues to perform well, with a strong balance sheet and solid bottom line performance.
“While the board believes the company’s valuation will, in time, reflect the true value of its business, a thorough review of strategic alternatives is a prudent step to enhance that process.”
Neo added that the outcome and timing of the review are not guaranteed.
It noted that the company has not set a timetable for the review's completion and plans to withhold further comments until it deems additional disclosure necessary or appropriate.
Neo also said it has appointed John McGarva to its board after discussions with Hastings Technology Metals, a significant shareholder.
Despite the timing, the company clarified that McGarva's appointment and the review are not at Hastings' behest.
McGarva brings leadership experience in product development and manufacturing across various industries.
Kennedy added: “We look forward to welcoming John McGarva to the board as an independent director.
“He will bring a wealth of experience and expertise to the board. We appreciate Hastings’ constructive engagement and consultation with the board in respect of Dr McGarva’s upcoming appointment.”
